Company intelligence / Profile preview

Supercede Therapeutics

New Castle, Delaware, USA

Ownership: Private
Development stage: Other

Overview

Lead program STX-001, an oral small molecule inhibitor of Activin receptor type II (ACTRII), has demonstrated preclinical efficacy in diet-induced obese mice, showing significant fat loss and preservation or increase of lean body mass; additional benefit observed in combination with GLP-1 agonists. Not yet entered clinical trials. Based on published studies (using monoclonal antibodies, not Supercede's molecules), ACTRII inhibition can significantly reduce fat while stimulating increases in muscle mass in patients with obesity[2][3][4].

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

STX-001

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Supercede Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Supercede Therapeutics.

Explore the full profile